PZRXQ (PhaseRx) Ending Cash Position: $5.26 Mil (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PhaseRx Ending Cash Position?

PhaseRx PZRXQ -99.00% Ending Cash Position is $5.26 Mil as of Sep. 2017.

PhaseRx's Ending Cash Position for the quarter that ended in Sep. 2017 was $5.26 Mil.

PhaseRx's quarterly Ending Cash Position declined from Mar. 2017 ($6.69 Mil) to Jun. 2017 ($4.94 Mil) but then increased from Jun. 2017 ($4.94 Mil) to Sep. 2017 ($5.26 Mil).

PhaseRx's annual Ending Cash Position increased from Dec. 2014 ($2.03 Mil) to Dec. 2015 ($3.29 Mil) and increased from Dec. 2015 ($3.29 Mil) to Dec. 2016 ($9.98 Mil).

PhaseRx Ending Cash Position Related Terms

PhaseRx Ending Cash Position Historical Data

* Premium members only.

The historical data trend for PhaseRx's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhaseRx Ending Cash Position Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
Ending Cash Position
2.03 3.29 9.98

PhaseRx Quarterly Data
Mar15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Ending Cash Position Get a 7-Day Free Trial 8.64 9.98 6.69 4.94 5.26

PhaseRx Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

PhaseRx's Ending Cash Position for the fiscal year that ended in Dec. 2016 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3.29+6.693
=9.98

PhaseRx's Ending Cash Position for the quarter that ended in Sep. 2017 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4.941+0.316
=5.26

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $5.26 Mil mean?
PhaseRx (PZRXQ) has a Ending Cash Position of $5.26 Mil as of Sep. 2017. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on PhaseRx and its competitors.
Is PhaseRx's Ending Cash Position too high?
PhaseRx's current Ending Cash Position is $5.26 Mil.
How does PhaseRx's Ending Cash Position compare to NSPX and HSTC?
PhaseRx's Ending Cash Position of $5.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on PhaseRx and its competitors. PhaseRx's current Ending Cash Position is $5.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhaseRx stock overvalued right now?
PhaseRx (PZRXQ) has a current Ending Cash Position of $5.26 Mil. The current Ending Cash Position is $5.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For PhaseRx (PZRXQ), the current Ending Cash Position is $5.26 Mil as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PhaseRx Business Description

Address 410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.